Home › Uveal Melanoma › Colorado
Uveal Melanoma clinical trials in Colorado
7 studies for Uveal Melanoma are looking for participants at sites in Colorado.
Cities in Colorado
Tebentafusp in HLA-A*0201 Positive Previously Untreated Metastatic Uveal Melanoma
- University of Colorado Cancer Center, Aurora
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 9, 2026 · NCT06070012A Study to Investigate the Safety and Efficacy of IOV-3001 in Adults With Advanced Melanoma Who Will Receive Lifileucel
- SCRI Oncology Partners- Denver, Denver
RecruitingPhase 1/2
Ages 18 to 70 · All sexes · Updated Jun 15, 2026 · NCT06940739Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions
- SCRI - Denver, Denver
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Jun 8, 2026 · NCT03947385ACTengine® IMA203/IMA203CD8 as Monotherapy or in Combination With Nivolumab in Recurrent and/or Refractory Solid Tumors
- University of Colorado, Anschutz Medical Campus, Aurora
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated May 13, 2026 · NCT03686124Neoadjuvant Darovasertib in Primary Uveal Melanoma
- University of Colorado Hospital, Aurora
- The Melanoma and Skin Cancer Institute, Englewood
RecruitingPhase 3
Ages 18 and older · All sexes · Updated May 6, 2026 · NCT07015190A Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal Melanoma
- University of Colorado Hospital - Anschutz Cancer Pavilion(ACP), Aurora
- The Melanoma & Skin Cancer Institute, Englewood
RecruitingPhase 2/3
All ages · All sexes · Updated Apr 2, 2026 · NCT06581406Evaluation of the Safety, Efficacy, and Pharmacokinetics of NBM-BMX in Patients With Metastatic Uveal Melanoma
- Sarah Cannon Research Institute (SCRI) - Denver HealthONE Location, Denver
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Nov 28, 2025 · NCT07136181From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.